Articles

Poll

Podcasts

Slideshows

Videos

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Discover how structured routines and exercise enhance mental health for those with bipolar disorder, fostering stability, and community support.

Treating Bipolar Disorder Requires a Treatment Team, Not Just a Treatment Plan

In this Q&A, Augsten discusses treatment strategies, challenges, and non-pharmacological interventions for schizophrenia and bipolar I disorder based on recent survey findings.

Alberto Augsten, PharmD, Interprets National Provider Survey on Schizophrenia, BD

A 2024 survey finds that most healthcare providers believe quality of life should be considered as much as symptom control when managing bipolar I disorder and schizophrenia.

Survey: Providers Prioritize QoL, Long-Term Care in BPD, Schizophrenia

This month in review covers key psychiatry updates, including the latest FDA decisions, antidepressant use in pregnancy, and the latest episode of Medical Ethics Unpacked.

Psychiatry Month in Review: February 2025 

Teva and Medincell announced FDA acceptance of their sNDA for UZEDY, a risperidone extended-release injectable, to treat adults with bipolar I disorder.

FDA Accepts sNDA for Risperidone Extended-Release Injectable Suspension for Bipolar I Disorder

A study found long-acting injectables reduced mean Young Mania Rating Scales scores in adolescents with bipolar mania from 33.8 at baseline to 21.7 at month 1.

Long-Acting Injectables Effectively Manage Bipolar Mania in Adolescents

Uric acid levels, commonly used to indicate gout, are closely associated with bipolar-affected mania.

Serum Uric Acid May Be Biomarker for Bipolar Affective Disorder

Unlike approved antidepressant drugs which have warnings on their labels stating they may increase the suicide risk, NRX-101 demonstrates meaningful reductions in suicidality.

NRX-101: First Antidepressant to Lower Suicidality in Bipolar Depression

Four-year, phase 3 data from APA 2024 show olanzapine/samidorphan provided consistent antipsychotic efficacy and weight-related safety in patients with either schizophrenia or bipolar I disorder. 

Olanzapine/Samidorphan Maintains Mood Disorder Efficacy, Weight and Glycemic Tolerability at 4 Years

The FDA approved iloperidone for acute treatment of bipolar I disorder on April 02, 2024, according to Vanda Pharmaceuticals.

FDA Approves Iloperidone (Fanapt) for Acute Treatment of Bipolar I Disorder

The HCPLive bipolar disorder page is a resource for medical news and expert insights on BPD. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for bipolar disease, and more.